ArticleJournal of ophthalmic inflammation and infection2026
Culture-proven endogenous endophthalmitis: ocular and systemic clinical features and outcomes.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the clinical presentation, systemic associations, microbiologic spectrum, management strategies, and treatment outcomes of patients with culture-proven endogenous endophthalmitis.
methodsA retrospective review of medical records was conducted of patients with culture-proven endogenous endophthalmitis between 2013 and 2024. Data collected included demographics, systemic and ocular findings, culture results, imaging studies, management strategies, and treatment outcomes.
resultsA total of 50 eyes from 41 patients were identified. Of these, 30/41 (73%) presented in an outpatient setting. The most common presenting symptom was blurred vision in 36/41 (88%) with only 16/41 (39%) presenting with systemic symptoms. Vitreous cultures disclosed fungal organisms in 19/41 (46%) of cases and bacterial in the remainder. Blood cultures were positive in 23/41 (56%). A systemic source of infection was identified in 23/41 (56%), most often associated with indwelling medical devices in 7/23 (30%). Intravenous drug use was present in 7/41 (17%). All patients received intravitreal antimicrobials and 25/50 (50%) underwent vitrectomy. Death associated with systemic infection occurred in only 3/41 (7%) of patients. Evisceration was performed in 2/50 (4%) eyes. Visual acuity at last follow up was ≥ 20/400 in 26/50 (52%) of eyes.
conclusionsEndogenous endophthalmitis was associated with a fungal source in 46% of cases and was not associated with systemic symptoms in 61% of cases. In the current study, indwelling medical devices remain an important source of infection. Despite prompt treatment, visual outcomes were generally poor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.